Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × Atomoxetine Hydrochloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Cisplatin 18 Carboplatin 12 Radiotherapy 11 Paclitaxel 10 Fluorouracil 9 Rituximab 7 Gemcitabine 7 Drug Therapy 6 Capecitabine 5 Bevacizumab 5 Vinorelbine 4 Nivolumab 4 Docetaxel 4 spartalizumab 3 pertuzumab 3 pembrolizumab 3 Trastuzumab 3 Standard of Care 3 Pemetrexed 3 Oxaliplatin 3 Methotrexate 3 Etoposide 3 Dexamethasone 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 Cetuximab 3 Bendamustine Hydrochloride 3 tislelizumab 2 ribociclib 2 parsaclisib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00255138 2022-04-01

Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects

Temple University

Phase 3 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡